The latest trading session saw Danaher (DHR) ending at $245.94, denoting a -0.75% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.72%. At the same time, the Dow lost 1%, and the tech-heavy Nasdaq lost 0.95%. The industrial and medical device maker's shares have seen a decrease of 3.28% over the last month, not keeping up with the Conglomerates sector's gain of 2.78% and the S&P 500's gain of 2.16%. The upcoming earnings release of Danaher will be of gr ...

WASHINGTON, March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading ...

Danaher (DHR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this industrial and medical device maker have returned +0.4% over the past month versus the Zacks S&P 500 composite's +3.6% change. The Zacks Diversified Operations industry, to which Danaher belongs, has gained 6.5% over this period. Now the key question is: Where could the stock be headed in ...

Danaher (DHR) closed the most recent trading day at $251.47, moving +0.83% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Meanwhile, the Dow experienced a rise of 0.2%, and the technology-dominated Nasdaq saw an increase of 0.82%. The industrial and medical device maker's shares have seen a decrease of 0.24% over the last month, not keeping up with the Conglomerates sector's gain of 5.08% and the S&P 500's gain of 1.76%. Analysts and investor ...

公司业绩 - Danaher Corporation (DHR) 受益于生命科学部门的强劲表现，主要受到学术和生命科学研究市场稳定需求的推动[1] - 公司新产品如IDBS的Polar Insight和Molecular Devices的CellXpress.ai受到积极回应，有助于加快药物发现过程，更快地推出新疗法[2] - DHR通过收购来加强和扩大业务。2023年12月，Danaher以57亿美元收购了全球蛋白消耗品供应商Abcam plc，这一收购扩大了公司的生命科学部门[3]

公司表现 - Danaher (DHR) 最新收盘价为 $252.80，较前一天下跌了 -0.35% [1] - 过去一个月，该公司的股价上涨了 4.42%，表现不及综合企业部门的 7.86% 增长，但优于标普500指数的 2.7% 增长 [2] 财务预期 - 分析师和投资者将密切关注 Danaher 即将公布的财报。预计每股收益 (EPS) 为 $1.74，较去年同期下降了 26.27%；预计营收为 $5.64 亿美元，较去年同期下降了 21.31% [3] - 根据 Zacks Consensus Estimates，预计全年每股收益为 $7.63，营收为 $240.9 亿美元，分别较去年增长了 +0.66% 和下降了 -12.73% [4] 分析师评级 - 投资者应注意近期分析师对 Danaher 的预期调整。这些修订反映了短期业务趋势的不断变化，正面修订表明分析师对公司业绩和利润潜力的信心 [5] - Zacks Rank 系统从 1 (强热门) 到 5 (强卖出)，自 1988 年以来， 1 股票的年均回报率为 +25%。目前，Danaher 的 Zacks Rank 为 3 (持有) [7] 估值和行业比较 - 公司目前的前瞻市盈率为 33.25，较行业平均前瞻市盈率 17.86 有溢价 [7] - DHR 目前的 PEG 比率为 3.85，与市盈率类似，PEG 比率也考虑了公司的预期盈利增长。该行业的平均 PEG 比率为 2.25 [8] 行业排名 - 多元化运营行业属于综合企业部门，目前该行业的 Zacks Industry Rank 为 51，在 250 多个行业中排名前 21% [9] - Zacks Industry Rank 通过测量各个行业组内个别股票的平均 Zacks Rank 来评估我们各个行业组的实力。研究显示，排名前 50% 的行业的表现是排名后 50% 的两倍 [10] 提示 - 切记利用 Zacks.com 来及时了解这些股票变动指标等信息 [11]

业绩总结 - 公司在2024年预计生物制药领域的核心有机销售将出现低个位数下降，而诊断领域将增长[2] - 公司预计2024年中国的生物制药领域销售将下降中至高个位数，而其他全球市场将保持稳定或略微下降[4] - 预计2024年运营利润率将提高50个基点[7] 用户数据 - 中国市场GeneXpert仪器安装基数超过5万台[6] - GeneXpert在医院设置中取得份额增长[6] - 预计2025年将为市场带来更多正常增长[6] - 高青少年增长率主要归因于呼吸道测试和其他测试项目[6] - 预计呼吸道市场的收入水平将接近1.5亿至1.6亿美元[6] - 非呼吸道业务增长率持续在20%以上[6] - 预计长期增长率为低两位数[6] 未来展望 - 预计2025年将为市场带来更多正常增长[6] - 预计长期增长率为低两位数[6] - 预计2024年运营利润率将提高50个基点[7] - 长期增长预期为高个位数[7] - 中国市场仍被视为有吸引力的市场[7]

公司表现 - Danaher (DHR) 是近期 Zacks.com 上搜索量最高的股票之一[1] - 公司股价在过去一个月中表现为 +3.3%，略低于 Zacks S&P 500 综合指数的 +5.2% 变化[2] 盈利预期 - 重点关注公司的盈利预期修订情况，因为我们认为股票的公平价值取决于未来盈利的现值[3] - 分析显示，当公司的盈利预期上升时，股票的公平价值也会上升，投资者倾向于购买股票，导致股价上涨[4]

A month has gone by since the last earnings report for Danaher (DHR) . Shares have added about 6.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Danaher due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Danaher Q4 Earnings Beat, Biotechnology Sales Dip Y/Y Danaher ...

Danaher (DHR) ended the recent trading session at $255.71, demonstrating a +0.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 0.17%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq lost 0.55%. The industrial and medical device maker's shares have seen an increase of 4.05% over the last month, not keeping up with the Conglomerates sector's gain of 7.17% and outstripping the S&P 500's gain of 3.98%. The investment community will be payi ...